Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Director | June 01, 2026 | June 03, 2026 |
| Aprea Therapeutics, Inc.APRE · Entity 7948 | Director | June 16, 2026 | June 17, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | May 05, 2023 | May 09, 2023 |
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Director | January 25, 2020 | January 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 139,302 |
Ending reported balance
After 2026-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-01 · Grant · Acquired 45,000 · Balance 151,902 F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-03 · Tax withholding · Disposed 12,600 · Balance 139,302 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.
Aprea Therapeutics, Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,180 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 3,135 · Balance 4,180 F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2036-06-16 | Direct | 12,555 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 12,555 · Balance 12,555 F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
HALOZYME THERAPEUTICS, INC.
Report date May 05, 2023 · Filed May 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,815 |
Reported balance
After 2023-05-05 transaction · row 1
1 source rowRow 1 · 2023-05-05 · Grant · Acquired 8,065 · Balance 66,815 F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $31.00 · Expires 2033-05-05 | Direct | 11,371 |
Reported balance
After 2023-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-05 · Grant · Acquired 11,371 · Balance 11,371 F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.
PALVELLA THERAPEUTICS, INC.
Report date January 25, 2020 · Filed January 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2030-01-25 | Direct | 20,000 |
Reported balance
After 2020-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-25 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 17, 2026 23:04 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 12,555 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001104659-26-075281 · tm2618211-4_4seq1.xml · derivative · entry 2 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,555 Underlying: Common Stock · 12,555 shares Expires 2036-06-16 F2 · derivative.exercise_date: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 23:04 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075281 · tm2618211-4_4seq1.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,180 F1 · shares: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 21:02 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 12,600 | $3.08 | $38,808.00 |
DisclosureSEC source: 0001628280-26-040488 · wk-form4_1780520540.xml · nonDerivative · entry 2 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,302 F2 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:02 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040488 · wk-form4_1780520540.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,902 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:00 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 12,600 | $3.58 | $45,108.00 |
DisclosureSEC source: 0001628280-25-031891 · wk-form4_1750194047.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,902 F1 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 4,185 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-25-057806 · tm2517366-1_4seq1.xml · derivative · entry 2 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2035-06-05 F2 · derivative.exercise_date: The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 1,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-057806 · tm2517366-1_4seq1.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,045 F1 · shares: These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:09 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029735 · wk-form4_1749157731.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,502 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:43 UTC | ADC Therapeutics SA ADCT · Entity 6502 | SaleCommon Shares | 6,995 | $2.89 | $20,215.55 |
DisclosureSEC source: 0001628280-24-028992 · wk-form4_1718761422.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,502 F1 · kind: Represents Common Shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:44 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-028355 · wk-form4_1718401463.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,497 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 01:47 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001104659-23-095014 · tm2324788-3_4seq1.xml · derivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-08-23 F1 · derivative.exercise_date: These options shall vest in full on the two year anniversary of the grant date, subject to the reporting person's continued service on the Issuer's board of Directors through and including the applicable vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007687 · form4-05092023_100516.xml · derivative · entry 2 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007687 · form4-05092023_100516.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,815 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2022 Filed May 7, 2022 00:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 6,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002906 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,750 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| August 25, 2021 Filed Aug 25, 2021 21:54 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 35,000 | $41.01 | $1,435,455.00 |
DisclosureSEC source: 0001179110-21-008418 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,544 Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004969 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,544 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 30, 2020 Filed May 1, 2020 23:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005375 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,314 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 25, 2020 Filed Jan 28, 2020 21:19 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001562180-20-000620 · primarydocument.xml · derivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| May 02, 2019 Filed May 3, 2019 20:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 12,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005497 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,485 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2020 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 22:35 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001562180-19-000571 · primarydocument.xml · derivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-25 F1 · derivative.exercise_date: The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| May 02, 2018 Filed May 2, 2018 23:39 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 10,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006086 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,312 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 2, 2019 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 21:40 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001562180-18-000482 · primarydocument.xml · derivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30 and December 31, 2018. Read SEC document |
| May 04, 2017 Filed May 5, 2017 20:52 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 14,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006686 · edgar.xml · nonDerivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,949 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 4, 2018 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| January 25, 2017 Filed Jan 31, 2017 00:05 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0000899243-17-002208 · doc4.xml · derivative · entry 1 BIZZARI JEAN-PIERRE · CIK 0001630914 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.